Fenelidone (Keshenda) is generally safest and most effective after taking it for several months.

Finerenone (Finerenone) is an oral selective mineral cortical receptor antagonist (MRA), mainly used for the treatment of patients with chronic kidney disease (CKD) accompanied by type 2 diabetes. Its mechanism of action is by antagonizing mineral cortical receptors in the kidneys and cardiovascular tissues, reducing inflammation and fibrosis, thereby delaying the decline of renal function and reducing the risk of cardiovascular events. Compared with traditional spironolactone drugs, fenelidone has a lower risk of raising blood potassium and has a more significant cardio-renal protective effect.

In terms of the taking period, clinical studies have shown that the efficacy of fenelinone can initially appear in the first few months of medication. However, in order to observe stable efficacy and safety, it is generally recommended to continue taking the medication for 3 to 6 months or more. During this period, the patient's renal function, blood potassium levels and blood pressure need to be monitored regularly to detect potential adverse reactions in a timely manner. According to data from large clinical trials such as FIDELIO-DKD and FIGARO-DKD, after 3 months of continuous use of fenelidone, most patients can observe a trend of decreased urinary protein, slowed renal function and reduced risk of cardiovascular events.

In terms of safety, fenelidone performs well in both short- and medium-term use, but elevated serum potassium is still the main risk that needs attention, especially in patients with renal insufficiency or concurrent use of ACEI/ARB. During the first 3 months, serum potassium and renal function should be tested every 1 to 2 weeks to ensure that the dosage is adjusted appropriately; the monitoring interval can be extended thereafter. If serum potassium is significantly elevated or renal function is significantly reduced, the medication needs to be temporarily discontinued or the dosage adjusted to ensure patient medication safety.

In general, the efficacy of fenelidone in patients with chronic kidney disease and type 2 diabetes can be observed through continuous use for 3 to 6 months, and the renal and cardiovascular protective effects are maintained during extended treatment. Clinically, individualized assessment and regular monitoring should be combined to ensure optimal efficacy within a safe dose range. Through scientific management of medication cycles and observation of efficacy, fenelidone can become an important drug choice for long-term intervention in patients with chronic kidney disease.
Reference link:https://www.drugs.com